Abstract 707P
Background
Although oral targeted therapies used in oncology demonstrate high interpatient variability in pharmacokinetics (PK), resulting in overdosing (>15%) and underdosing (30%) of patients (pts), a standard fixed dose for all pts is still used. This could lead to unnecessary toxicity and decreased efficacy, considering the established exposure–response and –toxicity relationships for many of these drugs. Personalised dosing through therapeutic drug monitoring (TDM) – individual dose adjustments based on measured PK–levels – could improve treatment outcomes. Results of 600 pts were published last year (Groenland et al, Ann Oncol. 1071-82, 2022 Oct). We hereby provide results of additional enrolment up to a 1000 pts, longer follow–up and newly reviewed cohorts.
Methods
This ongoing prospective study focusses on the feasibility, efficacy and tolerability of TDM of multiple oral targeted therapies in oncology. PK–levels are measured at 4–8–12 weeks after start of treatment and every 12 weeks thereafter. Recommendations are given based on established efficacy targets. Recommended interventions include dose adjustments, intake with food, split of intake moments, emphasize compliance and adjustment of interacting medication. An intervention is considered successful if there is a PK–level above target after intervention and if there is no dose limiting toxicity observed within one month.
Results
As of May 1st 2023, this study includes 1006 pts from 14 hospitals using one of 24 different oral targeted therapies. The largest cohorts are abiraterone (n = 189), imatinib (n = 165), sunitinib (n = 112) and pazopanib (n = 106). Among 916 evaluable pts, 41.3% (n = 378) had all PK–levels above target, while 58.7% (n = 538) had ≥1 PK–level below target. A PK-guided intervention was possible in 55.4% (n = 298), and was successful in 69.1% of cases. Of all pts with a PK-level below target, intervention was successful in 38.3%. As a result, there was a 22.5% gain in pts with PK-levels above target, reaching a total of 63.8% (n = 584).
Conclusions
The results of this study support the feasibility of TDM of oral targeted therapies in oncology. Before implementation, efficacy of TDM still requires further evaluation. For the largest cohorts this evaluation will be performed.
Clinical trial identification
Netherlands Trial Register NTR6866, Release date: 6 December 2017.
Editorial acknowledgement
Legal entity responsible for the study
Netherlands Cancer Institute-Antoni van Leeuwenhoek.
Funding
Unrestricted Research Grants from Ipsen, GSK, Merck, Novartis, Pfizer, Roche.
Disclosure
P. Hamberg: Financial Interests, Personal, Advisory Board: Astellas, MSD, Pfizer, AstraZeneca, BMS, Ipsen. H. Gelderblom: Financial Interests, Institutional, Invited Speaker: Daiichi Sankyo, Deciphera, Novartis, Boehringer Ingelheim, AmMax Bio, Debiopharm, Cytovation. A.K.L. Reyners: Financial Interests, Institutional, Other, Member of the board: Dutch Society of Medical Oncology; Financial Interests, Institutional, Invited Speaker, FIRST study; coordinator for the Netherlands: Tesaro; Financial Interests, Institutional, Invited Speaker, Local PI GCT1015-05 study: Genmab; Financial Interests, Institutional, Invited Speaker, Local PI for the RUBY study: Tesaro; Financial Interests, Institutional, Invited Speaker, Local PI of the R2810 study: Regeneron; Financial Interests, Institutional, Invited Speaker, PI of MK3475-C93 trial: Merck; Non-Financial Interests, Leadership Role, Chairperson of the group that advises the Dutch Society of Medical Oncology whether EMA authorised medication should be common practice in the Netherlands (cieBOM): Dutch Society of Medical Oncology. N.P. Van Erp: Financial Interests, Institutional, Invited Speaker: Wad 'n Workshop; Financial Interests, Institutional, Invited Speaker, IDS: Ipsen, Astellas. R.H. Mathijssen: Financial Interests, Institutional, Research Grant, Investigator-initiated research: Astellas, Bayer, Cristal Therapeutics, Pfizer, Roche, Sanofi, Servier, Boehringer-Ingelheim, Novartis; Financial Interests, Institutional, Invited Speaker: Pamgene. N. Steeghs: Financial Interests, Institutional, Advisory Board: Boehringer Ingelheim, Cogent Biosciences, Ellipses Pharma, Luszana; Financial Interests, Institutional, Invited Speaker: AbbVie, Actuate Therapeutics, Amgen, Array, Ascendis Pharma, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, BridgeBio, Bristol Myers Squibb, Cantargia, CellCentric, Cogent Biosciences, Crescendo Biologics, Cytovation, Deciphera, Dragonfly, Eli Lilly, Exelixis, Genentech, GSK, IDRx, Immunocore, Incyte, InteRNA, Janssen, Kinnate Biopharma, Kling Biotherapeutics, Luszana, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Navire Pharma, Novartis, Numab Therapeutics, Pfizer, Relay Pharmaceuticals, Revolution Medicin, Roche, Sanofi, Seattle Genetics, Taiho, Takeda; Financial Interests, Institutional, Research Grant: AstraZeneca, Bayer, Deciphera, GSK, Merck, Novartis, Pfizer. All other authors have declared no conflicts of interest.
Resources from the same session
126P - Biliary tract cancer (BTC) characterization on a cohort of patients (pt) from the Spanish RETUD Registry
Presenter: Adelaida Lacasta
Session: Poster session 17
127P - Prognostic significance of intratumoral and peritumoral budding in distal extrahepatic bile duct carcinoma
Presenter: Sun-Young Jun
Session: Poster session 17
128P - Biliary tract cancers: Epidemiological and prognosis trends of Latin American population
Presenter: Maria del Consuelo Diaz Romero
Session: Poster session 17
129P - Prognostic factors associated with survival in resected biliary tract cancers: A multicentre Italian experience
Presenter: Michele Ghidini
Session: Poster session 17
663P - Safety and preliminary efficacy of the KRAS G12C Inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC
Presenter: Carlos Rojas
Session: Poster session 17
664P - Final results of a phase I/II study of combined BCL-xL and MEK inhibition with navitoclax and trametinib in KRAS or NRAS mutant advanced solid tumors
Presenter: Ryan Corcoran
Session: Poster session 17
666P - Updated efficacy and safety data of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (fp) solid tumours
Presenter: Shun Lu
Session: Poster session 17
667P - Efficacy and safety of larotrectinib (laro) as first-line treatment for patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer
Presenter: David Hong
Session: Poster session 17